Fagron NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
11 mei 2015 - 07:00
Statutaire naam
Fagron NV
Titel
Fagron NV: Acquisition of AnazaoHealth in the United States
Bericht
Specialized in nuclear and pain medicine compounding
Regulated information
Waregem (Belgium)/Rotterdam (Netherlands)1, 11 May 2015
Fagron is pleased to announce that it has signed an agreement to acquire AnazaoHealth, a leading sterile compounding pharmacy in the United States specialized in nuclear, pain and intrathecal compounding. The products of AnazaoHealth are serviced to hospitals and specialized surgery clinics and therefore not impacted by reimbursement policies. For 2015, AnazaoHealth expects a turnover of approximately US$ 30 million with an EBITDA margin equal to the average of the Fagron Group. Fagron pays a multiple of 6 times EBITDA with 40% of the total consideration paid in Fagron shares valued at a minimum of € 40 per share; 20% of the total price is earn out based on the performance in 2015, payable in the first quarter of 2016. This acquisition is expected to be closed in the second quarter of 2015.
Datum laatste update: 21 december 2025